Full-Time

Vice President

Translational Science

Confirmed live in the last 24 hours

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharmaceuticals for eye and infectious diseases

Biotechnology
Healthcare

Compensation Overview

$259.5k - $363.3kAnnually

+ Bonus + Stock Equity + Comprehensive Benefits

Expert

Irvine, CA, USA

Hybrid work environment with in-office presence required.

Category
Computational Biology
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MD/PhD degree in Biology, Pharmacology, Molecular or Cell biology or related life sciences field with 15+ years’ experience and a minimum of 10+ years in the pharmaceutical or industry setting.
  • In-depth understanding and recognized scientific leader with expertise in scientific drug development for assets progressing through pre-clinical and IND-enabling studies and/or Phase I/II trials.
  • Superior knowledge and solid understanding of emerging research, mechanisms of action and disease models in anterior and posterior segment eye care diseases, preclinically and clinically.
  • Knowledge of the clinical landscape in ophthalmology indications with good understanding of novel agents and impact to this landscape.
  • Excellent oral and written communication skills, including writing, reviewing, and editing scientific documents.
  • Superior interpersonal skills, diplomacy, and positive-influencing abilities.
  • Exceptional communication, influencing and partnering skills to drive decision-making within a multi-disciplinary, matrix teams.
  • Ability to demonstrate effective leadership behaviors to ensure effective outcomes, including business agility as well as a curious, open-minded, and solution focused mindset.
  • Effective project management skills.
  • Strong presentation skills; must be able to provide succinct, strategic, and actionable insights to senior executives.
  • Proactive self-starter who can lead work independently, with the ability to see the next step and anticipate issues.
  • Scientifically independent.
  • Enterprise and entrepreneurial mindset.
Responsibilities
  • Subject Matter Expert in Pharmacology, Pathophysiology and drug target biology for both anterior and posterior segment diseases.
  • Establish and maintain strong external partnerships with key opinion leaders, academic institutions and other external partners and be seen as a scientific thought leader in the field of ophthalmology.
  • Partner with key internal experts across the company including Clinical Development, Innovation Lab and Business Development (BD) to drive translational strategy from preclinical development through candidate selection and contribute to translational strategies in early clinical development through early Proof of Concept.
  • Establish stage-appropriate project translational strategy for a differentiated asset to address unmet patient need with key 'Go/No Go' decision points.
  • Design and execute non-clinical experiments to support MOA-related translational questions as well as overall understanding of the disease treatment approaches.
  • Build and develop deep internal expertise in disease areas within ophthalmology, which are prioritized by the company. Identify possible mechanisms, disease models, preclinical POC approaches.
  • Generate clear, testable translational hypothesis to address unmet needs (mechanism of action, pharmacodynamics, patient selection).
  • Identify most relevant models, liaise with the best CRO and interact with academic experts to evaluate potential assets.
  • In collaboration with clinical development, define translational strategy on projects with the objective to guide clinical development: indication identification, patient stratification strategy, combination potential, optimization of dose selection, overall biomarker strategy, etc.
  • In partnership with clinical development, build the differentiation strategy for the therapeutic as well as defining the clinical and mechanism of action hypothesis and disease indication selection for early clinical development.
  • Contribute to hypothesis-driven study design, execution, and data analysis, including identification of most relevant preclinical and ex vivo models.
  • Identify key scientific questions in the projects and builds translation sciences plan according to their priority level.
  • Partner with BD and bring scientific expertise to evaluate and triage external assets and opportunities, identify main risk and mitigation plan and build additional evidence to enable Go/No Go decisions.
  • Partner with Innovation Lab team to prioritize various hypothesis, identify possible assets, generate evidence to enable advancement into clinical development.
  • Build open relationships with peers and external partners to ensure best decision making.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution for treating Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for other conditions, including Lyme Disease Prevention and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. Their goal is to improve patient outcomes by providing effective treatments for conditions that currently have limited options.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

Irvine, California

Founded

2017

Growth & Insights
Headcount

6 month growth

25%

1 year growth

33%

2 year growth

236%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $200 million in non-dilutive financing from Pharmakon Advisors strengthens Tarsus's financial position, enabling further R&D and market expansion.
  • Positive Phase 2a trial results for TP-05 for Lyme Disease prevention indicate promising future product offerings and potential market growth.
  • Recognition through awards like the Zero to Launch Award highlights Tarsus's innovative approach and successful commercialization strategies.

What critics are saying

  • The biopharmaceutical market is highly competitive and capital-intensive, requiring continuous innovation and substantial investment to maintain a competitive edge.
  • Dependence on the success of a limited number of products, such as XDEMVY, makes the company vulnerable to market fluctuations and regulatory changes.

What makes Tarsus Pharamceuticals unique

  • Tarsus Pharmaceuticals focuses on high unmet medical needs in eye care and infectious diseases, setting it apart from competitors with broader but less specialized portfolios.
  • Their flagship product, XDEMVY, is FDA-approved for treating Demodex Blepharitis, a niche condition with limited treatment options, giving them a unique market position.
  • The company's commitment to ethical operations and robust compliance programs ensures trust and reliability among healthcare providers and patients.

Help us improve and share your feedback! Did you find this helpful?